GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (MEX:AGIO) » Definitions » Float Percentage Of Total Shares Outstanding

Agios Pharmaceuticals (MEX:AGIO) Float Percentage Of Total Shares Outstanding : 98.60% (As of Apr. 13, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Agios Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Agios Pharmaceuticals's float shares is 56.50 Mil. Agios Pharmaceuticals's total shares outstanding is 57.30 Mil. Agios Pharmaceuticals's float percentage of total shares outstanding is 98.60%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Agios Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Agios Pharmaceuticals's Institutional Ownership is 57.99%.

Agios Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Agios Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=56.50/57.30
=98.60%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (MEX:AGIO) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
TVTX JANX VERA IRON ARQT ARWR HRMY KYMR MNKD IDYA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
AGIO:USA 0HB0:UK 8AP:Germany 8AP:Germany
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Website
https://www.agios.com
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.